
A study examined ocular adverse events associated with phosphodiesterase type 5 (PDE5) inhibitors—sildenafil, vardenafil, and tadalafil—using the FDA Adverse Event Reporting System (FAERS) data. Among 61,211 reports, sildenafil, vardenafil, and tadalafil exhibited increased reporting odds ratios for ocular adverse events. Vardenafil showed the highest risk (ROR 4.47), followed by sildenafil and tadalafil. Key events included cyanopsia, optic ischemic neuropathy, visual field defects, and blindness. Sildenafil notably had the highest disproportionality for cyanopsia. Time-to-onset analysis revealed differences, with sildenafil showing a later median onset. These findings provide valuable insights into the distinct ocular safety profiles of PDE5 inhibitors, aiding healthcare decision-making.
Like
Save
Share